Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (Becton, Dickinson and Company), a top medical technology firm, will present at the Cowen 43rd Annual Healthcare Conference on March 6, 2023, at 9:50 AM Eastern Time. Investors can access the live webcast on BD's investor relations website. A replay will be available after the event. BD focuses on advancing healthcare with innovative technologies and services, supporting healthcare professionals in improving patient outcomes. With a global workforce of 77,000, BD addresses key health challenges through collaborations worldwide. For more details, visit bd.com.
BD (NYSE: BDX) has received FDA approval for its Onclarity™ HPV Assay, designed for use with the ThinPrep® Pap Test. This assay is uniquely capable of individually identifying a broader range of HPV types, including the high-risk HPV31, which significantly enhances the ability to assess cervical cancer risk. The Onclarity™ HPV Assay’s approval supports BD's strategy to grow in the molecular diagnostics market. It detects 14 high-risk HPV types, providing crucial insights for clinical decision-making. The assay is validated through a large real-world study, improving both screening efficacy and women’s health management.
Summary not available.
BD (NYSE: BDX) announced FDA Emergency Use Authorization for a new molecular diagnostic test that identifies SARS-CoV-2, Influenza A+B, and Respiratory Syncytial Virus (RSV). This test, designed for the BD MAX™ System, allows for rapid diagnosis using a single nasal or nasopharyngeal swab, with results available in as little as two hours. It aims to streamline testing during respiratory virus seasons and enhance clinical treatment strategies. The BD MAX™ System is already widely utilized across hospitals and laboratories, capable of analyzing hundreds of samples daily.
BD (NYSE: BDX) announced the launch of the BD Rhapsody™ HT Xpress System designed for single-cell multiomics analysis, enabling researchers to conduct high-throughput studies with improved sample integrity. This new system can analyze up to eight times more cells than previous models, allowing simultaneous analysis of various cell types like stem and cancer cells. The system will be showcased at the AGBT General Meeting from February 6-9, 2023, in Hollywood, Florida. Additionally, BD is introducing the BD Rhapsody™ Mouse TCR/BCR Multiomic Assay and BD® Flex Single-Cell Multiplexing Kits to enhance data collection capabilities.
BD (Becton, Dickinson and Company) reported first-quarter fiscal 2023 revenues of $4.6 billion, a 2.8% decline year-over-year, while base business revenue increased by 0.4%. Diluted EPS decreased to $1.70 from $1.90, and adjusted diluted EPS fell to $2.98 from $3.17. Despite these declines, the company raised its full-year revenue guidance to $19.1 billion - $19.3 billion and adjusted EPS to $12.07 - $12.32, indicating resilience and strong execution of its BD 2025 strategy. The outlook anticipates continued currency-neutral growth of 5.75% - 6.75% in its base business.
BD (NYSE: BDX) has released its 2022 Cybersecurity Annual Report, emphasizing the company's commitment to enhancing cybersecurity measures in healthcare. The report focuses on transparency and collaboration, detailing efforts to protect patient safety and privacy amidst rising cyber threats like ransomware and phishing. Key highlights include BD's coordinated vulnerability disclosure processes, collaborations with cybersecurity working groups, and proactive measures against emerging risks. The report aims to empower customers by providing essential information on managing cyber risks effectively.
The Board of Directors of Becton, Dickinson and Company (NYSE: BDX) has declared a quarterly dividend of $0.91 per common share, scheduled for payment on March 31, 2023. This will benefit shareholders on record as of March 10, 2023, translating to an indicated annual dividend rate of $3.64 per share. BD remains a leader in global medical technology, focusing on enhancing health through improved medical discovery and diagnostics, serving healthcare providers worldwide.
BD (Becton, Dickinson and Company) has launched the 3rd Generation BD Kiestra™ Total Lab Automation System, designed to enhance laboratory efficiency and flexibility. This new robotic track system automates lab specimen processing, aiming to reduce manual tasks and turnaround times. The system features customizable configurations to fit various laboratory workflows and spaces, utilizing BD Synapsys™ informatics for integrated data analysis. Notable improvements include eliminating manual sorting and optimizing workflows, potentially impacting productivity positively.
BD (Becton, Dickinson and Company) has received Emergency Use Authorization (EUA) from the FDA for a new molecular PCR assay to detect the Mpox virus. This authorization allows the BD MAX™ System users to conduct timely diagnostics, enhancing the ability to combat the Mpox outbreak, designated a global health emergency by the WHO. The BD MAX™ System can process up to 24 samples in under three hours, offering multiple tests for various infections. This development is part of BD's commitment to improving diagnostics and healthcare delivery.